UnitedHealth (New York Stock Exchange: United Nations) stock It has fallen all the way below the level it was at Warren Buffett Berkshire Hathaway (New York Stock Exchange: BRKB), established its position in 2025.
It is worth noting, Berkshire acquired 5,039,564 UnitedHealth shares during the second quarter of 2025, a new stake worth $1.57 billion when the deal was unveiled in mid-August.
At the end of June 2025, when the quarter closed, UnitedHealth shares finished at $311. By press time, the stock was trading at $259, a decline of about 17%.
To that end, this decline resulted in an unrealized loss of $267 million on the position from the closing value on June 30.
In fact, Berkshire purchased the shares sometime between April and June 2025. Microtransaction prices were not disclosed at Organizational filings, but the buying occurred while UnitedHealth was already under intense pressure and trading well below its 2024 highs above $600.
the investment It marks Berkshire’s first significant ownership of the health insurer since it sold its previous stake in 2010 after building out a seed position in late 2006.
UN stock problems
Notably, UnitedHealth’s problems escalated throughout 2025 and created an opportunity for Buffett’s contrarian bet.
The company’s Medicare ratio rose from the mid-80% range to nearly 89% as claims costs accelerated beyond expectations, driven by increased utilization of deferred care after the pandemic and higher expenses in its Medicare Advantage business.
UnitedHealth repeatedly cut its 2025 earnings guidance, suspended the outlook entirely in May, and ultimately delivered results that fell well short of Wall Street expectations.
During the same period, CEO Andrew Witty resigned for personal reasons and was replaced by former Chairman Stephen Hemsley.
Adding to the pressure, the Justice Department opened a criminal investigation into potential Medicare fraud and billing practices at the company’s Medicare Advantage operations, following an earlier civil investigation.
Overall, the combination of rising medical costs, regulatory scrutiny and repeated earnings disappointments has wiped out more than a third of UnitedHealth’s market value through 2025 and left the stock vulnerable even after Berkshire’s buyout.
